

Supplementary Tables

Supplementary Table 1. mdNLR and mortality^a for all lung cancer cases and by histotype, excluding those who developed lung cancer within two years of blood draw.

mdNLR	All lung cases ^b			Adenocarcinoma			Squamous cell carcinoma			Small cell		
	Death N	Case N	HR (95% CI)	Death N	Case N	HR (95% CI)	Death N	Case N	HR (95% CI)	Death N	Case N	HR (95% CI)
Lung cancer-specific mortality												
Continuous	250	299	0.98 (0.89, 1.07)	86	112	1.10 (0.89, 1.36)	82	99	0.92 (0.81, 1.05)	59	62	1.21 (0.96, 1.53)
Q1 (lowest inflammation)	67	81	Ref	27	38	Ref	16	18	Ref	20	20	Ref
Q2	56	71	0.88 (0.61, 1.27)	16	23	0.83 (0.43, 1.61)	20	26	0.69 (0.33, 1.46)	16	17	1.21 (0.58, 2.51)
Q3	61	71	1.05 (0.74, 1.50)	19	21	1.17 (0.63, 2.19)	21	26	0.92 (0.44, 1.92)	12	14	1.39 (0.60, 3.20)
Q4 (highest inflammation)	66	76	1.08 (0.76, 1.56)	24	30	1.24 (0.67, 2.32)	25	29	0.66 (0.34, 1.30)	11	11	3.54 (1.37, 9.14)
	P-trend 0.51			P-trend 0.34			P-trend 0.39			P-trend 0.03		
All-cause mortality												
Continuous	285	299	0.98 (0.90, 1.06)	101	112	1.12 (0.94, 1.35)	97	99	0.91 (0.81, 1.03)	62	62	1.19 (0.95, 1.50)
Q1 (lowest inflammation)	76	81	Ref	33	38	Ref	18	18	Ref	20	20	Ref
Q2	67	71	0.92 (0.66, 1.29)	20	23	0.86 (0.47, 1.56)	26	26	0.80 (0.40, 1.60)	17	17	1.28 (0.63, 2.62)
Q3	69	71	1.07 (0.77, 1.49)	20	21	1.07 (0.60, 1.92)	25	26	0.99 (0.50, 1.99)	14	14	1.44 (0.64, 3.25)
Q4 (highest inflammation)	73	76	1.03 (0.73, 1.45)	28	30	1.24 (0.70, 2.19)	28	29	0.65 (0.34, 1.24)	11	11	3.37 (1.33, 8.57)
	P-trend 0.68			P-trend 0.38			P-trend 0.27			P-trend 0.03		

Abbreviations: HR = Hazard Ratio, mdNLR = methylation-derived neutrophil-to-lymphocyte ratio

^aMortality is estimated using Cox proportional hazards models adjusted for age, sex, smoking status, pack years at blood draw, and time between blood draw and diagnosis. Stage (early (I/II), late (III/IV), unknown) is included as a strata variable.

^b"All lung cancer cases" includes adenocarcinoma, squamous cell, and small cell, as well as 16 cases for whom histotype was NSCLC, NOS and 12 cases with unknown histotype.

Supplementary Table 2. Participating CARET Institutions and Federalwide Assurance Numbers by Study Center

Study center	Institution(s)	Federalwide Assurance Number (FWA)
Seattle	Fred Hutchinson Cancer Research Center, Seattle, Washington	1920
	University of Washington, Seattle, Washington	6878
Baltimore	University of Maryland, Baltimore, Maryland	7145
Portland	Kaiser Foundation Research Institute on behalf of Kaiser Foundation Hospitals (Kaiser Permanente Center for Health Research, Portland, Oregon was the CARET-specific site)	2344
New Haven	Yale University, New Haven, Connecticut	2571
	Lawrence & Memorial Hospital, New London, Connecticut	3097
San Francisco	University of California, San Francisco, California	68
Irvine	University of California, Irvine, California	4071